DAWN Day One Biopharmaceuticals, Inc. revenue, earnings and financials

For the quarter ended December 31, 2025, Day One Biopharmaceuticals, Inc. reported revenue of $53.7M (up 83.9% from a year earlier), net income of −$107B and diluted EPS of −$0.21; over the last four quarters revenue was $158M and net income −$107B; for the fiscal year ended December 2025 revenue was $158M, up 20.6% on the year before.

DAWN annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $158M, gross profit n/a, operating income −$128M, net income −$107B (margin -67847.2%), EPS −$1.04
• Fiscal year ended Dec 2024: revenue $131M, gross profit n/a, operating income −$217M, net income −$95.5B (margin -72808.2%), EPS −$1.02
• Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$206M, net income −$189B (margin n/a), EPS −$2.37
• Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$147M, net income −$142B (margin n/a), EPS −$2.17
• Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$72.7M, net income −$72.8B (margin n/a), EPS −$4.62

DAWN quarterly revenue and earnings

• Quarter ended Dec 31, 2025 (from the annual report): revenue $53.7M (up 83.9% year over year), net income −$107B, EPS −$0.21
• Quarter ended Sep 30, 2025: revenue $39.8M (down 57.6% year over year), net income −$19.7M, EPS −$0.19
• Quarter ended Jun 30, 2025: revenue $33.9M (up 313.9% year over year), net income −$30.3M, EPS −$0.29
• Quarter ended Mar 31, 2025: revenue $30.8M, net income −$36.0M, EPS −$0.35
• Quarter ended Dec 31, 2024 (from the annual report): revenue $29.2M, net income −$95.5B, EPS −$0.63
• Quarter ended Sep 30, 2024: revenue $93.8M, net income $37.0M, EPS $0.38
• Quarter ended Jun 30, 2024: revenue $8.19M, net income −$4.41M, EPS −$0.05
• Quarter ended Mar 31, 2024: revenue $0, net income −$62.4M, EPS −$0.72
• Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$189B, EPS −$0.63
• Quarter ended Sep 30, 2023: revenue $0, net income −$46.2M, EPS −$0.54
• Quarter ended Jun 30, 2023: revenue n/a, net income −$45.9M, EPS −$0.61
• Quarter ended Mar 31, 2023: revenue n/a, net income −$42.4M, EPS −$0.59
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$142B, EPS −$0.56
• Quarter ended Sep 30, 2022: revenue n/a, net income −$37.8M, EPS −$0.53
• Quarter ended Jun 30, 2022: revenue n/a, net income −$36.5M, EPS −$0.60
• Quarter ended Mar 31, 2022: revenue n/a, net income −$27.7M, EPS −$0.48
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$72.7B, EPS $3.33
• Quarter ended Sep 30, 2021: revenue n/a, net income −$19.2M, EPS −$0.33
• Quarter ended Jun 30, 2021: revenue n/a, net income −$15.5M, EPS −$5.04
• Quarter ended Mar 31, 2021: revenue n/a, net income −$15.2M, EPS −$2.58

DAWN cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$104M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$78.1M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$147M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$110M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$48.5M, share buybacks n/a

DAWN balance sheet

• Dec 31, 2025: cash $197M, total assets $508M, total liabilities $66.7M, shareholders' equity $441M
• Sep 30, 2025: cash $43.3M, total assets $514M, total liabilities $62.9M, shareholders' equity $451M
• Jun 30, 2025: cash $35.6M, total assets $519M, total liabilities $58.2M, shareholders' equity $461M
• Mar 31, 2025: cash $33.4M, total assets $534M, total liabilities $54.8M, shareholders' equity $480M
• Dec 31, 2024: cash $125M, total assets $583M, total liabilities $80.0M, shareholders' equity $503M
• Sep 30, 2024: cash $423M, total assets $601M, total liabilities $45.3M, shareholders' equity $555M
• Jun 30, 2024: cash $240M, total assets $400M, total liabilities $93.7M, shareholders' equity $307M
• Mar 31, 2024: cash $270M, total assets $327M, total liabilities $29.8M, shareholders' equity $297M

What is DAWN's revenue?

Day One Biopharmaceuticals, Inc. reported $158M of revenue over its last four quarters, through December 31, 2025.

Is DAWN profitable?

No. Day One Biopharmaceuticals, Inc. lost $107B over the last four quarters.

What is DAWN's EPS?

Diluted earnings per share over the last four quarters were −$1.04; −$0.21 in the latest quarter.

DAWN ownership and insider trades · All stocks